Xenon Pharmaceuticals (XENE) Q2 FY26 earnings call: guidance and Q&A

Asked for a recap of the FDA pre-NDA meeting for AZK and any notable outcomes.

Management confirmed a productive and positive in-person meeting with the FDA, achieving alignment on NDA package components, and remains on track for submission this quarter. No specific concerns were raised by the agency.

“We covered the main questions that we wanted to cover with FDA as it pertains to the submission. We continue to believe that we have a very strong package and that overall, it's a pretty straightforward package that we're bringing to the agency.”

asked by Paul Matteis (Stifel) · answered by Christopher Kenney

Inquired about the safety profile of XEN1701, specifically regarding cardiac AEs, and the rationale for advancing a second Nav1.7 candidate (XEN1720).

Management stated they are comfortable with XEN1701's safety profile for moving into Phase 2, having seen no dose-limiting cardiac AEs. They confirmed central drug exposure via CSF. XEN1720 offers a differentiated chemistry profile and analysis of selectivity, potency, protein binding, and PK, providing multiple "shots on goal" for this high-value target.

“Again, today, what we see in the data is that it's a profile that we're very comfortable moving ahead into a Phase 2 proof-of-concept study. So that's taking everything into consideration.”

asked by Paul Matteis (Stifel) · answered by Ian Mortimer

Asked for more detail on when general neurologists are expected to adopt AZK and specific education efforts to ensure a good initial experience.

Management believes AZK's profile (novel mechanism, ease of use, strong efficacy/safety) makes it compelling for general neurologists, potentially leading to earlier adoption than historically seen. They are highly focused on expediting utilization and plan to offer innovative services, such as assistance with prior authorization and patient support, to overcome traditional barriers and ensure a positive experience.

“When you couple the efficacy safety along with our open-label extension seizure freedom data, it really is a package that they're really compelled by. I think we have this opportunity to do that.”

asked by Joseph Thome (TD Cowen) · answered by Darren Cline

Inquired about payer conversations, potential pricing benchmarks, and receptivity to premium pricing for AZK given its profile advantages.

Management noted that AZK would be the first focal onset seizure medication approved in almost a decade. Payer discussions focus on re-educating them on unmet needs. Payers are impressed with AZK's profile. While pricing work is ongoing, the company believes there's an opportunity for premium pricing given the value, efficacy, and safety, while also ensuring patient access.

“We feel early days that there is an opportunity to ensure we get the value out of Azetukalner, while also, though, ensuring that patients can access the drug and physicians feel confident writing it.”

asked by Brian Abrahams (RBC Capital Markets) · answered by Darren Cline

Asked for confirmation that sufficient data exists for all four planned AZK doses on label and how the X-CEED bipolar trial handles patients who experience mania.

Management stated that the FDA had no concerns about inadequate exposures for any of the planned doses and believes they have a robust package for all four doses. For the X-CEED trial, patients who meet a certain cutoff on the YMRS (Young Mania Rating Scale) are typically discontinued from the study, following a standard protocol.

“I mean, Myles, thanks for the question. A lot of this stuff will be dealt with in the review, but there were no concerns from the agency specifically about inadequate exposures in any way.”

asked by Myles Minter (William Blair) · answered by Christopher Kenney